,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Nivolumab,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolized by intestinal enzymes and by the microbial flora. ",(See Summary)
1,Nivolumab,Acenocoumarol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
2,Nivolumab,Acetylsalicylic acid (Aspirin),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolized by glucuronidation (by several UGTs, major UGT1A6). Nivolumab does not inhibit or induce CYPs or UGTs.",(See Summary)
3,Nivolumab,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Nivolumab does not inhibit or induce CYPs.",(See Summary)
4,Nivolumab,Alendronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alendronic acid is excreted via urine. Nivolumab does not interact with this pathway.,(See Summary)
5,Nivolumab,Alfentanil,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Nivolumab does not inhibit or induce CYPs.,(See Summary)
6,Nivolumab,Alfuzosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfuzosin is metabolized by CYP3A. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
7,Nivolumab,Aliskiren,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. Additionally, aliskiren is a substrate of P-gp. Nivolumab does not interact with this pathway.",(See Summary)
8,Nivolumab,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Allopurinol is also an inhibitor of xanthine oxidase. Nivolumab does not interact with this pathway.,(See Summary)
9,Nivolumab,Alosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2. Nivolumab does not inhibit or induce CYPs.",(See Summary)
10,Nivolumab,Alprazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
11,Nivolumab,Aluminium hydroxide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aluminium hydroxide is not metabolised. Nivolumab does not interfere with this metabolic pathway.,(See Summary)
12,Nivolumab,Ambrisentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is metabolised by glucuronidation via UGTs 1A3, 1A9 and 2B7 and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. Nivolumab does not inhibit or induce UGTs, CYPs or P-gp.",(See Summary)
13,Nivolumab,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Amikacin is eliminated by glomerular filtration therefore no pharmacokinetic interaction is expected with nivolumab.,(See Summary)
14,Nivolumab,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Nivolumab is unlikely to significantly inhibit amiloride renal elimination.,(See Summary)
15,Nivolumab,Amiodarone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiodarone is metabolised by CYP3A4 and CYP2C8. The major metabolite of amiodarone, desethylamiodarone, is an inhibitor of CYPs 3A4 (weak), 2C9 (moderate), 2D6 (moderate), 2C19 (weak), 1A1 (strong) and 2B6 (moderate). Nivolumab does not interact with this pathway.",(See Summary)
16,Nivolumab,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally (possibly via OCT). Nivolumab is unlikely to significantly impair amisulpride elimination. ,(See Summary)
17,Nivolumab,Amitriptyline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19, with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. Nivolumab does not inhibit or induce CYPs.",(See Summary)
18,Nivolumab,Amlodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
19,Nivolumab,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Nivolumab is unlikely to interfere with amoxicillin renal elimination.,(See Summary)
20,Nivolumab,Amphotericin B,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as amphotericin B is not appreciably metabolized and is eliminated to a large extent in the bile. Nivolumab does not interfere with amphotericin B elimination pathway.However, the European SPC for amphotericin states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension. Monitoring may be required.",(See Summary)
21,Nivolumab,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20 to 40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60 to 80% is excreted in the urine within 6 hours. Nivolumab is unlikely to significantly inhibit ampicillin renal elimination.,(See Summary)
22,Nivolumab,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperature. ,(See Summary)
23,Nivolumab,Antacids,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Antacids are not metabolised by CYPs. Nivolumab does not interfere with this metabolic pathway.,(See Summary)
24,Nivolumab,Apixaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is a substrate of P-gp and BCRP and is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
25,Nivolumab,Aprepitant,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. During treatment, aprepitant is a moderate inhibitor of CYP3A4, but after treatment aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Nivolumab does not interact with this pathway.",(See Summary)
26,Nivolumab,Aripiprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
27,Nivolumab,Asenapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYPs 1A2 (major), 3A4 (minor) and 2D6 (minor)). Nivolumab does not inhibit or induce UGTs or CYPs.",(See Summary)
28,Nivolumab,Astemizole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as astemizole is metabolized by CYPs 2D6, 2J2 and 3A4. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
29,Nivolumab,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. ",(See Summary)
30,Nivolumab,Atorvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolized by CYP3A4 and is a substrate of P-gp and OATP1B1. Nivolumab does not inhibit or induce CYPs, P-gp or OATP1B1.",(See Summary)
31,Nivolumab,Azathioprine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolized analogously to natural purines. Nivolumab does not interfere with this metabolic pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered. Furthermore, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
32,Nivolumab,Azithromycin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion; animal data suggest this may occur via P-gp and MRP2. Azithromycin is also an inhibitor of P-gp, but the clinical relevance of P-gp inhibition is unknown. Nivolumab does not interact with this pathway.",(See Summary)
33,Nivolumab,Beclometasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate. Nivolumab does not interact with this metabolic pathway. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of beclometasone.",(See Summary)
34,Nivolumab,Bedaquiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bedaquiline is metabolised by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
35,Nivolumab,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically significant interaction is unlikely in the range of observed clinical concentrations. ,(See Summary)
36,Nivolumab,Bepridil,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Bepridil is metabolized by CYP2D6 (major) and 3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
37,Nivolumab,Betamethasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Betamethasone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of betamethasone.",(See Summary)
38,Nivolumab,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as half of bezafibrate dose is eliminated unchanged in the urine. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Nivolumab does not interact with this pathway. ,(See Summary)
39,Nivolumab,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. ,(See Summary)
40,Nivolumab,Bisoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
41,Nivolumab,Bosentan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bosentan is a substrate and weak inducer of CYP3A4 and CYP2C9. Nivolumab does not interact with this pathway.,(See Summary)
42,Nivolumab,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may play a role. Nivolumab does not inhibit or induce CYPs.",(See Summary)
43,Nivolumab,Budesonide,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Budesonide is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of budesonide.",(See Summary)
44,Nivolumab,Buprenorphine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Nivolumab does not inhibit or induce CYPs or UGTs.,(See Summary)
45,Nivolumab,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
46,Nivolumab,Buspirone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
47,Nivolumab,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. Nivolumab does not interact with this pathway. ",(See Summary)
48,Nivolumab,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. Nivolumab does not interact with this pathway.,(See Summary)
49,Nivolumab,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Nivolumab does not interfere with this elimination pathway.,(See Summary)
50,Nivolumab,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Nivolumab does not interact with this pathway.,(See Summary)
51,Nivolumab,Carbamazepine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbamazepine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2C8. Carbamazepine is also an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Nivolumab does not interact with this pathway.",(See Summary)
52,Nivolumab,Carvedilol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
53,Nivolumab,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
54,Nivolumab,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Nivolumab does not interfere with cefalexin renal elimination.,(See Summary)
55,Nivolumab,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Nivolumab does not interfere with cefazolin renal elimination.",(See Summary)
56,Nivolumab,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cefixime is renally excreted predominantly by glomerular filtration. Nivolumab does not interfere with cefixime renal elimination.,(See Summary)
57,Nivolumab,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Nivolumab does not interfere with cefotaxime renal elimination.",(See Summary)
58,Nivolumab,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ceftazidime is excreted predominantly by renal glomerular filtration. Nivolumab does not interfere with ceftazidime renal elimination.,(See Summary)
59,Nivolumab,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Nivolumab does not interfere with ceftriaxone renal elimination.",(See Summary)
60,Nivolumab,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolized by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
61,Nivolumab,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine inhibits OCT2. Nivolumab is unlikely to interact with cetirizine renal elimination.,(See Summary)
62,Nivolumab,Chloramphenicol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly glucuronidated. In vitro studies have shown that chloramphenicol can inhibit metabolism mediated by CYPs 3A4 (strong), 2C19 (strong) and 2D6 (weak). Nivolumab does not interact with this metabolic pathway.",(See Summary)
63,Nivolumab,Chlordiazepoxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce CYPs. Nivolumab does not inhibit or induce CYPs.",(See Summary)
64,Nivolumab,Chlorphenamine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver via CYP2D6. Nivolumab is unlikely to interact with chlorphenamine. ,(See Summary)
65,Nivolumab,Chlorpromazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
66,Nivolumab,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. ,(See Summary)
67,Nivolumab,Ciclosporin (Cyclosporine),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciclosporin is a substrate of CYP3A4 and P-gp and inhibits CYP3A4 and OATP1B1. Nivolumab does not interact with this pathway. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
68,Nivolumab,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. Nivolumab does not interact with this pathway.,(See Summary)
69,Nivolumab,Cimetidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cimetidine is metabolised by CYP enzymes. Cimetidine is also a weak inhibitor of several CYP enzymes (CYPs 3A4, 1A2, 2D6 and 2C19, among others). Furthermore, cimetidine may decrease the renal excretion of drugs due to competition for the active tubular secretion. In vitro data indicate that cimetidine also inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Nivolumab does not interact with this metabolic pathway.",(See Summary)
70,Nivolumab,Ciprofloxacin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. Ciprofloxacin is also metabolised and partially cleared through the bile and intestine. Nivolumab does not interfere with this elimination pathway. Furthermore, ciprofloxacin is a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Nivolumab is not metabolised by CYPs.",(See Summary)
71,Nivolumab,Cisapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolised by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
72,Nivolumab,Citalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%). Nivolumab does not inhibit or induce CYPs. ",(See Summary)
73,Nivolumab,Clarithromycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clarithromycin is metabolised by CYP3A4 and is also an inhibitor of CYP3A4 (strong) and P-gp. Nivolumab does not interact with this metabolic pathway.,(See Summary)
74,Nivolumab,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolized (likely non CYP mediated pathway) and excreted in the urine by glomerular filtration. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
75,Nivolumab,Clemastine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clemastine is predominantly metabolized in the liver via CYP2D6. Nivolumab is unlikely to interact with clemastine.,(See Summary)
76,Nivolumab,Clindamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4 and in vitro data suggest that it is a CYP3A4 inhibitor. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
77,Nivolumab,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,(See Summary)
78,Nivolumab,Clofazimine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces. In vitro data suggest that clofazimine is a CYP3A4 inhibitor. Nivolumab does not interact with this pathway.,(See Summary)
79,Nivolumab,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Nivolumab does not interfere with clofibrate elimination.",(See Summary)
80,Nivolumab,Clomipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYP3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
81,Nivolumab,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). Clonidine is a weak inhibitor of OCT2 but is unlikely to interact with nivolumab elimination. In addition, nivolumab does not interfere with clonidine elimination.",(See Summary)
82,Nivolumab,Clopidogrel,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug and is converted to its active metabolite mainly by CYP2C19 with CYPs 3A4, 2B6 and 1A2 playing a minor role. Clopidogrel is also an inhibitor of CYP2C8 (strong), CYP2B6 (weak) and of CYP2C9 (in vitro) at high concentrations. The clinical relevance of CYP2C9 inhibition is unknown. Nivolumab does not interact with this pathway.",(See Summary)
83,Nivolumab,Clorazepate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. Oxazepam is mainly glucuronidated. Nivolumab does not inhibit or induce CYPs or UGTs.,(See Summary)
84,Nivolumab,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Nivolumab does not interact with this metabolic pathway.",(See Summary)
85,Nivolumab,Clozapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. Nivolumab does not inhibit or induce CYPs. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
86,Nivolumab,Codeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Morphine is further metabolised by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Morphine is also a substrate of P-gp. Furthermore, codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. Nivolumab does not inhibit or induce CYPs, UGTs or P-gp.",(See Summary)
87,Nivolumab,Colchicine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as colchicine is metabolized by CYP3A4 and is a substrate of P-gp. Nivolumab does not interact with this pathway.,(See Summary)
88,Nivolumab,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly excreted renally via glomerular filtration. Nivolumab does not interact with this metabolic pathway.,(See Summary)
89,Nivolumab,Dabigatran,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is a substrate of P-gp and is renally excreted. Nivolumab does not inhibit or induce P-gp.,(See Summary)
90,Nivolumab,Dalteparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Nivolumab does not interfere with the renal excretion of dalteparin. ,(See Summary)
91,Nivolumab,Dapsone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
92,Nivolumab,Desipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
93,Nivolumab,Desogestrel,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
94,Nivolumab,Dexamethasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dexamethasone is a substrate of CYP3A4. Dexamethasone has also be described as an inducer of CYP3A4, but the induction of CYP3A4 by dexamethasone has not yet been established. Nivolumab does not interact with this pathway. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of dexamethasone.",(See Summary)
95,Nivolumab,Dextropropoxyphene,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
96,Nivolumab,Diamorphine (diacetylmorphine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Nivolumab does not inhibit or induce CYPs, UGTs or P-gp.",(See Summary)
97,Nivolumab,Diazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). Temazepam is mainly glucuronidated. Nivolumab does not inhibit or induce CYPs or UGTs.,(See Summary)
98,Nivolumab,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9. Nivolumab does not inhibit or induce CYPs or UGTs.,(See Summary)
99,Nivolumab,Digoxin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is eliminated renally via the renal transporters OATP4C1 and P-glycoprotein. Nivolumab does not interact with this pathway.,(See Summary)
100,Nivolumab,Dihydrocodeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. Nivolumab does not inhibit or induce CYPs or UGTs. ",(See Summary)
101,Nivolumab,Diltiazem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diltiazem is metabolized by CYP3A4 and CYP2D6. Additionally, diltiazem inhibits CYP3A4. Nivolumab does not interact with this pathway.",(See Summary)
102,Nivolumab,Diphenhydramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Diphenhydramine is also a weak inhibitor of CYP2D6. Nivolumab does not interact with this pathway.",(See Summary)
103,Nivolumab,Dipyridamole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Nivolumab does not to interfere with this pathway. ",(See Summary)
104,Nivolumab,Disopyramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. Nivolumab does not interact with this metabolic pathway.,(See Summary)
105,Nivolumab,Dolasetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). ",(See Summary)
106,Nivolumab,Domperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
107,Nivolumab,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Nivolumab does not interact with this pathway.",(See Summary)
108,Nivolumab,Doxazosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
109,Nivolumab,Doxepin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. In addition, doxepin and nordoxepin are metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
110,Nivolumab,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40%-60% of an administered dose can be accounted for in the urine. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
111,Nivolumab,Dronabinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
112,Nivolumab,Drospirenone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
113,Nivolumab,Dulaglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Nivolumab does not interact with this pathway. ,(See Summary)
114,Nivolumab,Duloxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
115,Nivolumab,Dutasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
116,Nivolumab,Dydrogesterone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Nivolumab does not inhibit or induce CYPs.,(See Summary)
117,Nivolumab,Edoxaban,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. Nivolumab does not inhibit or induce CYPs or P-gp.,(See Summary)
118,Nivolumab,Eltrombopag,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1, UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Nivolumab does not interact with this metabolic pathway.",(See Summary)
119,Nivolumab,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Nivolumab does not interact with this pathway.,(See Summary)
120,Nivolumab,Enoxaparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally. Nivolumab does not interact with this metabolic pathway.",(See Summary)
121,Nivolumab,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug. ,(See Summary)
122,Nivolumab,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor component. Nivolumab does not interact with this metabolic pathway.,(See Summary)
123,Nivolumab,Erythromycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erythromycin is a substrate of CYP3A4 and P-gp. Erythromycin is also an inhibitor of CYP3A4 (moderate) and P-gp. Nivolumab does not interact with this metabolic pathway.,(See Summary)
124,Nivolumab,Escitalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolized by CYP2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
125,Nivolumab,Esomeprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is metabolised by CYP2C19 and CYP3A4. Esomeprazole is also an inhibitor of CYP2C19. Nivolumab does not interact with this pathway.,(See Summary)
126,Nivolumab,Estazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
127,Nivolumab,Estradiol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Nivolumab does not inhibit or induce CYPs.",(See Summary)
128,Nivolumab,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%). Nivolumab does not interact with this metabolic pathway.,(See Summary)
129,Nivolumab,Ethinylestradiol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). Nivolumab does not inhibit or induce CYPs.",(See Summary)
130,Nivolumab,Ethionamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver, animal studies suggest involvement of flavin-containing monooxygenases. Nivolumab does not interfere with this pathway. ",(See Summary)
131,Nivolumab,Etonogestrel,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
132,Nivolumab,Everolimus (Immunosuppressant),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Everolimus is mainly metabolized by CYP3A4 and is a substrate of P-gp. Nivolumab does not inhibit or induce CYP3A4 or P-gp. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered. Furthermore, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
133,Nivolumab,Exenatide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is cleared mainly by glomerular filtration. Nivolumab does not interact with this pathway. ,(See Summary)
134,Nivolumab,Ezetimibe,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
135,Nivolumab,Famotidine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is excreted via OAT1/OAT3. Nivolumab does not inhibit or induce OATs.,(See Summary)
136,Nivolumab,Felodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
137,Nivolumab,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolyzed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Nivolumab does not interact with this pathway.",(See Summary)
138,Nivolumab,Fentanyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
139,Nivolumab,Fexofenadine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine is a substrate of P-gp. Nivolumab does not interact with this pathway.,(See Summary)
140,Nivolumab,Finasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
141,Nivolumab,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
142,Nivolumab,Flecainide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Flecainide is metabolized mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also eliminated unchanged renally. Nivolumab does not interact with this metabolic pathway.",(See Summary)
143,Nivolumab,Flucloxacillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Flucloxacillin has been described as a CYP3A4 inducer. Nivolumab does not interact with this metabolic pathway.,(See Summary)
144,Nivolumab,Fluconazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is renally excreted and inhibits CYPs 3A4 (moderate), 2C9 (strong) and 2C19 (moderate). Nivolumab does not interact with this pathway.",(See Summary)
145,Nivolumab,Flucytosine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase to an inactive metabolite. Nivolumab does not interfere with this elimination pathway. However, 5-FU binds to the enzyme thymidylate synthase resulting in DNA damage. This mechanism occurs in all fast dividing cells including bone marrow cells, resulting in haematological toxicity. Nivolumab also induces haematological toxicity which could be enhanced by the use of flucytosine. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
146,Nivolumab,Fludrocortisone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of fludrocortisone.",(See Summary)
147,Nivolumab,Flunitrazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and 2C19. Nivolumab does not inhibit or induce CYPs.,(See Summary)
148,Nivolumab,Fluoxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYP2D6 and CYP2C9 and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. Fluoxetine is a strong inhibitor of CYP2D6 and CYP2C19. Nivolumab does not interact with this pathway.,(See Summary)
149,Nivolumab,Fluphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
150,Nivolumab,Flurazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Nivolumab does not inhibit or induce CYPs.,(See Summary)
151,Nivolumab,Fluticasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fluticasone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of fluticasone.",(See Summary)
152,Nivolumab,Fluvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9 (75%) and to a lesser extent by CYP3A4 (20%) and CYP2C8 (5%). Fluvastatin potentially inhibits CYP2C9, but the clinical relevance of CYP2C9 inhibition is unknown. Nivolumab does not interact with this metabolic pathway.",(See Summary)
153,Nivolumab,Fluvoxamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Fluvoxamine is also an inhibitor of CYPs 1A2 (strong), 2C19 (strong), 3A4 (moderate), 2C9 (weak-moderate) and 2D6 (weak). Nivolumab does not interact with this pathway.",(See Summary)
154,Nivolumab,Fondaparinux,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally. Nivolumab does not interact with this metabolic pathway.,(See Summary)
155,Nivolumab,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. As multiple CYP450 and UGT enzymes catalyze the transformation the potential for a pharmacokinetic interaction is low. Nivolumab does not interact with this metabolic pathway.",(See Summary)
156,Nivolumab,Fosaprepitant,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. During treatment, aprepitant is a moderate inhibitor of CYP3A4, but after treatment aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Nivolumab does not interact with this pathway.",(See Summary)
157,Nivolumab,Fosphenytoin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Phenytoin is also a potent inducer of CYP3A4, UGT and P-gp. Nivolumab does not interact with this pathway.",(See Summary)
158,Nivolumab,Furosemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also renally eliminated unchanged (via OATs). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. In vitro data indicate that furosemide is also an inhibitor of OAT1/OAT3.  Nivolumab does not interfere with this elimination pathway.,(See Summary)
159,Nivolumab,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Nivolumab does not interact with this elimination pathway.,(See Summary)
160,Nivolumab,Gemfibrozil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Gemfibrozil is also an inhibitor of CYP2C8 (strong), OATP1B1 and OAT3. In vitro data indicate gemfibrozil to be a strong inhibitor of CYP2C9 but in vivo data showed no clinically relevant effect on CYP2C9. Nivolumab does not interact with this pathway.",(See Summary)
161,Nivolumab,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
162,Nivolumab,Gestodene,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Nivolumab does not inhibit or induce CYPs.,(See Summary)
163,Nivolumab,Glibenclamide (Glyburide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
164,Nivolumab,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
165,Nivolumab,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolized by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
166,Nivolumab,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolized by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
167,Nivolumab,Granisetron,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolized by CYP3A4 and is a substrate of P-gp. Nivolumab does not interact with this pathway.,(See Summary)
168,Nivolumab,Grapefruit juice,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Grapefruit juice is known to inhibit CYP3A4 enzymes. Nivolumab does not interact with this pathway.,(See Summary)
169,Nivolumab,Green tea,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
170,Nivolumab,Griseofulvin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Griseofulvin is also a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy of concomitantly administered medicinal products that are metabolised by CYPs. Nivolumab does not interact with this pathway.",(See Summary)
171,Nivolumab,Haloperidol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6). Nivolumab does not inhibit or induce CYPs. ",(See Summary)
172,Nivolumab,Heparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Nivolumab does not interact with this metabolic pathway.,(See Summary)
173,Nivolumab,Hydralazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. In vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6. It is not expected that this will lead to a clinical relevant interaction with nivolumab. ",(See Summary)
174,Nivolumab,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolized but is cleared by the kidneys via OAT1. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Significant interactions are not expected with nivolumab.,(See Summary)
175,Nivolumab,Hydrocodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
176,Nivolumab,Hydrocortisone (oral),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
177,Nivolumab,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,(See Summary)
178,Nivolumab,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
179,Nivolumab,Hydroxyurea (Hydroxycarbamide),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea is metabolized in the liver and cleared via the lung and kidney. Nivolumab does not interact with this pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
180,Nivolumab,Hydroxyzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
181,Nivolumab,Ibandronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibandronic acid is excreted via urine. Nivolumab does not interact with this pathway.,(See Summary)
182,Nivolumab,Ibuprofen,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Nivolumab does not inhibit or induce CYPs or UGTs. ,(See Summary)
183,Nivolumab,Iloperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolized by CYP3A4 and CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
184,Nivolumab,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and to a lesser extent, active tubular secretion. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
185,Nivolumab,Imipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
186,Nivolumab,Indapamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Nivolumab does not interact with this metabolic pathway.,(See Summary)
187,Nivolumab,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
188,Nivolumab,Interferon alpha,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically relevant pharmacokinetic interaction is unlikely. Coadministration may increase risk of neutropenia, fatigue, and thrombocytopenia. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
189,Nivolumab,Interleukin 2 (Aldesleukin),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Nivolumab does not interact with this pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
190,Nivolumab,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Nivolumab does not interact with this metabolic pathway.,(See Summary)
191,Nivolumab,Irbesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Significant interactions are not expected with nivolumab. ,(See Summary)
192,Nivolumab,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
193,Nivolumab,Isoniazid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
194,Nivolumab,Isosorbide dinitrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
195,Nivolumab,Itraconazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Itraconazole is metabolized by CYP3A4 and inhibits CYP3A4 (strong), CYP2C9 (weak), P-gp and BCRP. Nivolumab does not interact with this pathway.",(See Summary)
196,Nivolumab,Ivabradine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
197,Nivolumab,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration therefore no pharmacokinetic interaction is expected with nivolumab. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
198,Nivolumab,Ketoconazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoconazole is metabolized by CYP3A4 and is an inhibitor of CYP3A4 (strong) and P-gp. Nivolumab does not interact with this pathway.,(See Summary)
199,Nivolumab,Labetalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and 2B7). Nivolumab does not interact with this metabolic pathway. ,(See Summary)
200,Nivolumab,Lacidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
201,Nivolumab,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. ,(See Summary)
202,Nivolumab,Lansoprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
203,Nivolumab,Lercanidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
204,Nivolumab,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Nivolumab does not interact with this elimination pathway.,(See Summary)
205,Nivolumab,Levofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Levofloxacin is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2). Nivolumab does not interact with this metabolic pathway. ,(See Summary)
206,Nivolumab,Levomepromazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
207,Nivolumab,Levonorgestrel,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Nivolumab does not interact with this metabolic pathway.,(See Summary)
208,Nivolumab,Levonorgestrel (Emergency Contraception),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Nivolumab does not interact with this metabolic pathway.,(See Summary)
209,Nivolumab,Levothyroxine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Nivolumab does not interact with levothyroxine metabolism. ,(See Summary)
210,Nivolumab,Lidocaine (Lignocaine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
211,Nivolumab,Linagliptin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor elimination pathway. Linagliptin is also a substrate of P-gp and is a weak inhibitor of CYP3A4. Nivolumab does not interact with this pathway.,(See Summary)
212,Nivolumab,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non CYP mediated metabolism. ,(See Summary)
213,Nivolumab,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases. Nivolumab does not interact with this pathway. ,(See Summary)
214,Nivolumab,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration. Nivolumab does not interact with this pathway.,(See Summary)
215,Nivolumab,Lithium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. ,(See Summary)
216,Nivolumab,Live vaccines,"
Do Not Coadminister
","
Very Low
","Coadministration of live vaccines (such as BCG vaccine; measles, mumps and rubella vaccines; varicella vaccines; typhoid vaccines; rotavirus vaccines; yellow fever vaccines; oral polio vaccine) has not been studied. In patients, who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. If coadministration is judged clinically necessary, use with extreme caution since generalized infections can occur.",(See Summary)
217,Nivolumab,Loperamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolized by CYP3A4 and CYP2C8, and is a substrate of P-gp. Nivolumab does not interact with this pathway. ",(See Summary)
218,Nivolumab,Loratadine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
219,Nivolumab,Lorazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on non-CYP-mediated elimination pathways for lorazepam, no effect on plasma concentrations is expected upon coadministration with nivolumab. ",(See Summary)
220,Nivolumab,Lormetazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
221,Nivolumab,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
222,Nivolumab,Lovastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolised by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
223,Nivolumab,Macitentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
224,Nivolumab,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in kidney, mainly by glomerular filtration. ",(See Summary)
225,Nivolumab,Maprotiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
226,Nivolumab,Medroxyprogesterone (depot),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
227,Nivolumab,Medroxyprogesterone (non-depot),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
228,Nivolumab,Mefenamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Nivolumab does not inhibit or induce CYPs or UGTs. ,(See Summary)
229,Nivolumab,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. Nivolumab does not interact with this elimination pathway.,(See Summary)
230,Nivolumab,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3>OAT1. Nivolumab does not interfere with this elimination pathway. ,(See Summary)
231,Nivolumab,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase. Nivolumab does not interfere with this pathway. ,(See Summary)
232,Nivolumab,Metamizole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metamizole is metabolised by hydrolysis to the active metabolite MAA in the gastrointestinal tract. Metamizole is metabolised in serum and excreted via urine (90%) and faeces (10%). Metamizole is also an inducer of CYP3A4. Nivolumab does not interact with this metabolic pathway.,(See Summary)
233,Nivolumab,Metformin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine and is a substrate of OCT1/2/3, MATE1 and MATE2K.  Nivolumab does not interact with this pathway.",(See Summary)
234,Nivolumab,Methadone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methadone is demethylated by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
235,Nivolumab,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Nivolumab does not interact with this pathway.",(See Summary)
236,Nivolumab,Methylphenidate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolized by cytochrome P450 to a clinically relevant extent and does not inhibit cytochrome P450s. ,(See Summary)
237,Nivolumab,Methylprednisolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of methylprednisolone.",(See Summary)
238,Nivolumab,Metoclopramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Nivolumab does not interact with this metabolic pathway. ,(See Summary)
239,Nivolumab,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Nivolumab does not interact with this metabolic pathway.,(See Summary)
240,Nivolumab,Metoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
241,Nivolumab,Metronidazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metronidazole is eliminated via glomerular filtration. Elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, ciclosporin) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Nivolumab does not interfere with this pathway.",(See Summary)
242,Nivolumab,Mexiletine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
243,Nivolumab,Mianserin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
244,Nivolumab,Miconazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Miconazole is extensively metabolized by the liver. Miconazole is also an inhibitor of CYP2C9 (moderate) and CYP3A4 (strong). Nivolumab does not interact with this pathway.,(See Summary)
245,Nivolumab,Midazolam (oral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
246,Nivolumab,Midazolam (parenteral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
247,Nivolumab,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Nivolumab is unlikely to interfere with this pathway.",(See Summary)
248,Nivolumab,Mirtazapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Nivolumab does not inhibit or induce CYPs.",(See Summary)
249,Nivolumab,Mometasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mometasone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of mometasone.",(See Summary)
250,Nivolumab,Montelukast,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Nivolumab does not interact with this metabolic pathway.,(See Summary)
251,Nivolumab,Morphine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Nivolumab does not inhibit or induce UGTs or P-gp.",(See Summary)
252,Nivolumab,Moxifloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Nivolumab is unlikely to interfere with this pathway.,(See Summary)
253,Nivolumab,Mycophenolate,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. The active metabolite of mycophenolate, mycophenolic acid, is an inhibitor of OAT1/OAT3. Nivolumab does not interact with this pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered. Furthermore, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
254,Nivolumab,Nadroparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nadroparin is renally excreted by a nonsaturable mechanism. Nivolumab does not interact with this elimination pathway.,(See Summary)
255,Nivolumab,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolized in the liver by alpha-reductase. Nivolumab does not interact with this metabolic pathway.,(See Summary)
256,Nivolumab,Naproxen,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Nivolumab does not inhibit or induce CYPs or UGTs. ,(See Summary)
257,Nivolumab,Nateglinide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent CYP3A4 (30%). Nivolumab does not inhibit or induce CYPs.,(See Summary)
258,Nivolumab,Nebivolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
259,Nivolumab,Nefazodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nefazodone is metabolised by, and is a strong inhibitor of, CYP3A4. Nivolumab does not interact with this pathway.",(See Summary)
260,Nivolumab,Nicardipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Nicardipine is also a weak inhibitor of CYP3A4. Nivolumab does not interact with this pathway.,(See Summary)
261,Nivolumab,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolized by xanthine oxidase and aldehyde oxidase. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
262,Nivolumab,Nifedipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
263,Nivolumab,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Nivolumab does not inhibit or induce CYPs.,(See Summary)
264,Nivolumab,Nisoldipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
265,Nivolumab,Nitrendipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
266,Nivolumab,Nitrofurantoin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug (30-40%). Nivolumab does not interact with this metabolic pathway. ,(See Summary)
267,Nivolumab,Norelgestromin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Nivolumab does not inhibit or induce CYPs.,(See Summary)
268,Nivolumab,Norethisterone (Norethindrone),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
269,Nivolumab,Norgestimate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolized via CYP450. Nivolumab does not interact with this metabolic pathway.,(See Summary)
270,Nivolumab,Norgestrel,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolized by CYP3A4 and is glucuronidated to a minor extent. Nivolumab does not interact with this metabolic pathway.,(See Summary)
271,Nivolumab,Nortriptyline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
272,Nivolumab,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.",(See Summary)
273,Nivolumab,Ofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Ofloxacin is eliminated unchanged renally by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Nivolumab is unlikely to interfere with this pathway. ,(See Summary)
274,Nivolumab,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 (major) and CYP2D6, but also by glucuronidation (UGT1A4). Nivolumab does not inhibit or induce CYPs or UGTs.",(See Summary)
275,Nivolumab,Olmesartan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan, which is eliminated in the faeces and urine. Nivolumab does not interfere with this metabolic pathway.",(See Summary)
276,Nivolumab,Omeprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Omeprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Omeprazole is also an inducer of CYP1A2 and an inhibitor of CYP2C19. Nivolumab does not interact with this pathway.,(See Summary)
277,Nivolumab,Ondansetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Additionally, ondansetron is a substrate of P-gp. Nivolumab does not interact with this pathway.",(See Summary)
278,Nivolumab,Oxazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
279,Nivolumab,Oxcarbazepine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is extensively metabolized to the active metabolite monohydroxyderivate (MHD) through cystolic enzymes. Both oxcarbazepine and MHD are inducers of CYP3A4 (moderate) and CYP3A5, and are inhibitors of CYP2C19. Nivolumab does not interact with this metabolic pathway.",(See Summary)
280,Nivolumab,Oxprenolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolized via glucuronidation nivolumab does not interact with this metabolic pathway. ,(See Summary)
281,Nivolumab,Oxycodone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally to noroxycodone via CYP3A and oxymorphone via CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
282,Nivolumab,Paliperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and 3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
283,Nivolumab,Palonosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Palonosetron is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Additionally, palonosetron is a substrate of P-gp. Nivolumab does not interact with this pathway.",(See Summary)
284,Nivolumab,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronic acid is excreted via urine. Nivolumab does not interact with this pathway.,(See Summary)
285,Nivolumab,Pantoprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. Nivolumab does not inhibit or induce CYPs.",(See Summary)
286,Nivolumab,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
287,Nivolumab,Paracetamol (Acetaminophen),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (UGTs 1A9 (major), 1A6, 1A1, and 2B15) sulfation and to a lesser extent by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). Nivolumab does not inhibit or induce CYPs or UGTs.",(See Summary)
288,Nivolumab,Paroxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6. Paroxetine is an inhibitor of CYP2D6 (strong) and CYP2C9. Nivolumab does not interact with this pathway.,(See Summary)
289,Nivolumab,Peginterferon alfa-2a,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, coadministration may increase risk of neutropenia, fatigue, and thrombocytopenia. Haematological parameters should be monitored if used concurrently.",(See Summary)
290,Nivolumab,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Nivolumab does not interfere with elimination of penicillins.,(See Summary)
291,Nivolumab,Perazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is mainly metabolised by CYPs 1A2, 3A4 and 2C19, and to a lesser extent by CYPs 2C9, 2D6 and 2E1, with oxidation via FMO3. Nivolumab does not inhibit or induce CYPs or FMO3.",(See Summary)
292,Nivolumab,Periciazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
293,Nivolumab,Perindopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Elimination occurs predominantly via the urine. Nivolumab does not interact with this elimination pathway. ,(See Summary)
294,Nivolumab,Perphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
295,Nivolumab,Pethidine (Meperidine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
296,Nivolumab,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolized by oxidation via monoamine oxidase and to a lesser extent acetylation. Nivolumab does not interact with this metabolic pathway.,(See Summary)
297,Nivolumab,Phenobarbital (Phenobarbitone),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenobarbital is metabolized by CYP2C19 and CYP2C9 (major) and to a lesser extent by CYP2E1. Phenobarbital is also a strong inducer of CYPs 3A4, 2C9, 2C8 and UGTs. Nivolumab does not interact with this pathway.",(See Summary)
298,Nivolumab,Phenprocoumon,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolised by CYP2C9 and CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
299,Nivolumab,Phenytoin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Phenytoin is also a potent inducer of CYP3A4, UGT and P-gp. Nivolumab does not interact with this pathway.",(See Summary)
300,Nivolumab,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
301,Nivolumab,Pimozide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is mainly metabolised by CYP3A4 and CYP2D6 and to a lesser extent by CYP1A2. Nivolumab does not inhibit or induce CYPs.,(See Summary)
302,Nivolumab,Pindolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Nivolumab is not expected to interfere with pindolol elimination. ,(See Summary)
303,Nivolumab,Pioglitazone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
304,Nivolumab,Pipotiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)(See Summary)
305,Nivolumab,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
306,Nivolumab,Pitavastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolized by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Pitavastatin is also a substrate of OATP1B1. Nivolumab does not inhibit or induce UGTs, CYPs or OATP1B1.",(See Summary)
307,Nivolumab,Posaconazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is metabolized by UGTs and is a substrate of P-gp. Posaconazole is also a strong inhibitor of CYP3A4. Nivolumab does not interact with this pathway.,(See Summary)
308,Nivolumab,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is eliminated renally. ,(See Summary)
309,Nivolumab,Prasugrel,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. Nivolumab does not inhibit or induce CYPs.,(See Summary)
310,Nivolumab,Pravastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is minimally metabolised via CYP enzymes and is a substrate of OATP1B1. Nivolumab does not inhibit or induce CYPs or OATP1B1.,(See Summary)
311,Nivolumab,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolized, primarily by demethylation and conjugation. Nivolumab is unlikely to interact with prazosin. ",(See Summary)
312,Nivolumab,Prednisolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prednisolone undergoes hepatic metabolism via CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of prednisolone.",(See Summary)
313,Nivolumab,Prednisone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Nivolumab does not interact with this metabolic pathway. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of prednisone.",(See Summary)
314,Nivolumab,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration (90% as unchanged drug). Nivolumab is unlikely to interfere with this elimination pathway.,(See Summary)
315,Nivolumab,Prochlorperazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
316,Nivolumab,Promethazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized by CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
317,Nivolumab,Propafenone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2 and CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
318,Nivolumab,Propranolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Nivolumab does not interact with this metabolic pathway. ",(See Summary)
319,Nivolumab,Prucalopride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. Additionally, prucalopride is a substrate of P-gp. Nivolumab does not interact with this metabolic pathway.",(See Summary)
320,Nivolumab,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
321,Nivolumab,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
322,Nivolumab,Quetiapine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
323,Nivolumab,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Nivolumab does not impact this renal transporter. ,(See Summary)
324,Nivolumab,Quinidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2E1. Quinidine is also a substrate of P-gp and an inhibitor of CYP2D6 (strong), CYP3A4 (weak) and P-gp (moderate). Nivolumab does not interact with this pathway.",(See Summary)
325,Nivolumab,Rabeprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. Nivolumab does not interact with this metabolic pathway.,(See Summary)
326,Nivolumab,Ramipril,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Nivolumab is not expected to interfere with these metabolic pathways. ",(See Summary)
327,Nivolumab,Ranitidine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via OAT1/OAT3. Nivolumab does not inhibit or induce OATs.,(See Summary)
328,Nivolumab,Ranolazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Ranolazine is also a substrate of P-gp. Furthermore, ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Nivolumab does not interact with this pathway.",(See Summary)
329,Nivolumab,Reboxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. In vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. Nivolumab does not interact with reboxetine metabolic pathway. ,(See Summary)
330,Nivolumab,Repaglinide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYP2C8 and 3A4 and clinical data seem to indicate that it is a substrate of the hepatic transporter OATP1B1. Nivolumab does not interact with this metabolic pathways. ,(See Summary)
331,Nivolumab,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
332,Nivolumab,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
333,Nivolumab,Rifabutin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifabutin is metabolised by CYP3A and via deacetylation. Rifabutin is also a strong CYP3A4 and P-gp inducer. Nivolumab does not interact with this pathway.,(See Summary)
334,Nivolumab,Rifampicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifampicin is metabolised via deacetylation and is also a strong CYP3A4 and P-gp inducer. Nivolumab does not interact with this pathway.,(See Summary)
335,Nivolumab,Rifapentine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifapentine is metabolised via deacetylation and is also a strong CYP3A4, CYP2C8 and P-gp inducer. Nivolumab does not interact with this pathway.",(See Summary)
336,Nivolumab,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
337,Nivolumab,Risperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. Nivolumab does not inhibit or induce CYPs or P-gp.,(See Summary)
338,Nivolumab,Rivaroxaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine. Rivaroxaban is also a substrate of P-gp and BCRP. Nivolumab does not interact with this pathway.",(See Summary)
339,Nivolumab,Rosiglitazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent 2C9. Nivolumab does not inhibit or induce CYPs.,(See Summary)
340,Nivolumab,Rosuvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosuvastatin is largely excreted unchanged in the faeces via OATP1B1 and is a substrate of BCRP. Nivolumab does not interact with this metabolic pathway.,(See Summary)
341,Nivolumab,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4’-O-sulphate. Nivolumab does not interact with this metabolic pathway.,(See Summary)
342,Nivolumab,Salmeterol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
343,Nivolumab,Saxagliptin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4 and is a substrate of P-gp. Nivolumab does not interact with this pathway. ,(See Summary)
344,Nivolumab,Senna,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. ,(See Summary)
345,Nivolumab,Sertindole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertindole is metabolized by CYP2D6 and CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
346,Nivolumab,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Nivolumab does not inhibit or induce CYPs.",(See Summary)
347,Nivolumab,Sildenafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
348,Nivolumab,Simvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Simvastatin is also a substrate of BCRP and the active metabolite is a substrate of OATP1B1. Nivolumab does not inhibit or induce CYPs, BCRP or OATP1B1.",(See Summary)
349,Nivolumab,Sirolimus,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sirolimus is metabolized by CYP3A4 and is a substrate of P-gp. Nivolumab does not inhibit or induce CYPs or P-gp. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered. Furthermore, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
350,Nivolumab,Sitagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1 and P-gp) and metabolism by CYP3A4 represents a minor elimination pathway. Nivolumab does not interact with this pathway.",(See Summary)
351,Nivolumab,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. Nivolumab does not interact with this pathway.",(See Summary)
352,Nivolumab,Sotalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sotalol is excreted unchanged via renal elimination. Nivolumab does not interact with this pathway.,(See Summary)
353,Nivolumab,Spectinomycin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Nivolumab does not interact with this metabolic pathway. ",(See Summary)
354,Nivolumab,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases. Nivolumab does not interfere with this metabolic pathway. ,(See Summary)
355,Nivolumab,Stanozolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stanozolol undergoes hepatic metabolism. Nivolumab does not interact with this metabolic pathway.,(See Summary)
356,Nivolumab,St John's Wort,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. St John’s wort is a P-gp and CYP3A4 inducer. Nivolumab does not interact with this pathway.,(See Summary)
357,Nivolumab,Streptokinase,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Nivolumab is unlikely to interfere with this pathway.",(See Summary)
358,Nivolumab,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration therefore no pharmacokinetic interaction is expected with nivolumab. ,(See Summary)
359,Nivolumab,Sulfadiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Nivolumab does not interfere with sulfadiazine metabolism.,(See Summary)
360,Nivolumab,Sulpiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Nivolumab is unlikely to significantly impair sulpiride elimination.,(See Summary)
361,Nivolumab,Tacrolimus,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tacrolimus is metabolised mainly by CYP3A4. Tacrolimus also inhibits CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. Nivolumab does not interact with this pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered. Furthermore, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic immunosuppressants at baseline, before starting nivolumab, should be avoided. Immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.",(See Summary)
362,Nivolumab,Tadalafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
363,Nivolumab,Tamsulosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
364,Nivolumab,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Nivolumab does not interact with this elimination pathway.,(See Summary)
365,Nivolumab,Telithromycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telithromycin is a strong inhibitor of CYP3A4. Nivolumab does not interact with this pathway. ,(See Summary)
366,Nivolumab,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Nivolumab not interact with this metabolic pathway. ,(See Summary)
367,Nivolumab,Temazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
368,Nivolumab,Terbinafine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYP1A2, 2C9, 3A4 and to a lesser extent CYP2C8 and 2C19. Nivolumab does not inhibit or induce CYPs.",(See Summary)
369,Nivolumab,Testosterone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
370,Nivolumab,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Nivolumab does not interact with this elimination pathway. ,(See Summary)
371,Nivolumab,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Nivolumab does not inhibit or induce CYPs.,(See Summary)
372,Nivolumab,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
373,Nivolumab,Thioridazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
374,Nivolumab,Tiapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in urine. Nivolumab is unlikely to significantly impair tiapride elimination.,(See Summary)
375,Nivolumab,Ticagrelor,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4. Additionally, ticagrelor is a substrate of P-gp. Nivolumab does not interact with this pathway. ",(See Summary)
376,Nivolumab,Timolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6.Nivolumab does not interact with this metabolic pathway.  ,(See Summary)
377,Nivolumab,Tinzaparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Nivolumab does not interact with this elimination pathway.,(See Summary)
378,Nivolumab,Tolbutamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
379,Nivolumab,Tolterodine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
380,Nivolumab,Torasemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized mainly by CYP2C9. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Nivolumab does not interact with this metabolic pathway.",(See Summary)
381,Nivolumab,Tramadol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
382,Nivolumab,Trandolapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
383,Nivolumab,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration. ,(See Summary)
384,Nivolumab,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
385,Nivolumab,Trazodone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
386,Nivolumab,Triamcinolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Nivolumab does not inhibit or induce CYPs. However, immunosuppressants are suspected to lower the immunotherapy efficacy due to their immunosuppressive role. Therefore, use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. Systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. Note: No clinically relevant interactions are expected with local use of triamcinolone.",(See Summary)
387,Nivolumab,Triazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Nivolumab does not interact with this metabolic pathway. ,(See Summary)
388,Nivolumab,Trimethoprim/Sulfamethoxazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. To a lesser extent (approximately 30%) trimethoprim is metabolised by CYP-enzymes (in vitro data suggest CYPs 3A4, 1A2 and 2C9). Trimethoprim is a weak CYP2C8 inhibitor and in vitro data also suggest that trimethoprim is an inhibitor of OCT2 and MATE1. Sulfamethoxazole is metabolised via and is a weak inhibitor of CYP2C9. Nivolumab does not interact with this metabolic pathway.",(See Summary)
389,Nivolumab,Trimipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
390,Nivolumab,Tropisetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tropisetron is metabolized mainly by CYP2D6. Additionally, tropisetron is a substrate of P-gp. Nivolumab does not interact with this pathway.",(See Summary)
391,Nivolumab,Ulipristal,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
392,Nivolumab,Valproic acid (Valproate),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproic acid is primarily metabolised by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). To a lesser extent (10%) valproic acid is metabolised by CYP2C9 and CYP2C19. Valproic acid is also an inhibitor of CYP2C9. Nivolumab does not interact with this pathway.,(See Summary)
393,Nivolumab,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Nivolumab does not interact with this pathway.,(See Summary)
394,Nivolumab,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration therefore no pharmacokinetic interaction is expected with nivolumab. ,(See Summary)
395,Nivolumab,Venlafaxine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
396,Nivolumab,Verapamil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Verapamil is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Verapamil is a moderate inhibitor of CYP3A4, but nivolumab does not interact with this pathway.",(See Summary)
397,Nivolumab,Vildagliptin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vildagliptin is inactivated via non-CYP mediated hydrolysis and is a substrate of P-gp. Nivolumab does not interact with this pathway.,(See Summary)
398,Nivolumab,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
399,Nivolumab,Voriconazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is metabolized by CYP219 (major) and to a lesser extent by CYP2C9 and CYP3A4. Voriconazole is also a strong inhibitor of CYP3A4 and a weak inhibitor of CYPs 2C9, 2C19 and 2B6. Nivolumab does not interact with this pathway.",(See Summary)
400,Nivolumab,Warfarin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and 3A4. S-warfarin (more potent) is metabolised by CYP2C9. Nivolumab does not inhibit or induce CYPs. ,(See Summary)
401,Nivolumab,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Nivolumab does not interact with this metabolic pathway.",(See Summary)
402,Nivolumab,Zaleplon,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. Nivolumab does not inhibit or induce CYPs.,(See Summary)
403,Nivolumab,Ziprasidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Nivolumab does not inhibit or induce CYPs. ",(See Summary)
404,Nivolumab,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is excreted via urine. Nivolumab does not interact with this pathway.,(See Summary)
405,Nivolumab,Zolpidem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 1A2. Nivolumab does not inhibit or induce CYPs.",(See Summary)
406,Nivolumab,Zopiclone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Nivolumab does not inhibit or induce CYPs.,(See Summary)
407,Nivolumab,Zotepine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. Nivolumab does not inhibit or induce CYPs.,(See Summary)
408,Nivolumab,Zuclopenthixol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Nivolumab does not inhibit or induce CYPs. ",(See Summary)
